` ABVC (ABVC Biopharma Inc) vs S&P 500 Comparison - Alpha Spread

ABVC
vs
S&P 500

Over the past 12 months, ABVC has significantly outperformed S&P 500, delivering a return of +295% compared to the S&P 500's +13% growth.

Stocks Performance
ABVC vs S&P 500

Loading
ABVC
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ABVC vs S&P 500

Loading
ABVC
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABVC vs S&P 500

Loading
ABVC
S&P 500
Add Stock

Competitors Performance
ABVC Biopharma Inc vs Peers

S&P 500
ABVC
AMGN
ALNY
ARGX
603259
Add Stock

ABVC Biopharma Inc
Glance View

Market Cap
51.5m USD
Industry
N/A

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.

ABVC Intrinsic Value
0.1 USD
Overvaluation 97%
Intrinsic Value
Price
Back to Top